eNOS Polymorphisms May Influence Prognosis in Hepatocellular Carcinoma Treated with Sorafenib

Share this content:
eNOS VNTR and eNOS -786 could determine outcomes in advanced hepatocellular carcinoma treated with sorafenib,
eNOS VNTR and eNOS -786 could determine outcomes in advanced hepatocellular carcinoma treated with sorafenib,

SAN FRANCISCO—Endothelial nitric oxide synthase (eNOS) VNTR and eNOS -786 could determine outcomes in patients with advanced hepatocellular carcinoma treated with the tyrosine kinase inhibitor, sorafenib, a study (Abstract 230) presented this week at the 2015 Gastrointestinal Cancers Symposium has shown.

Cancer cells are known to adapt to hypoxic microenvironments by activating various molecules, such as eNOS. Sorafenib inhibits eNOS activity, thereby decreasing nitric oxide production and ultimately inhibiting tumor angiogenesis, tumor invasion, and metastasis.

For this study, researchers sought to investigate the effect of eNOS polymorphisms on clinical outcomes in patients with hepatocellular carcinoma treated with sorafenib.

RELATED: A New Approach to Assessing Liver Function in Hepatocellular Carcinoma

Researchers identified 54 patients treated with sorafenib for hepatocellular carcinoma between 2004 and 2014 and analyzed three eNOS polymorphisms (eNOS +894 G/T, eNOS VNTR 27bp 4a/b, eNOS -786 C/T) from peripheral blood samples or FFPE tumor tissues.

Results showed that patients with the ENOS VNTR b allele had increased overall survival compared with those that did not (4aa = 5.7 months, 4ab = 13.9 months, 4bb = 23.6 months; P = 0.016).

Patients with the eNOS -786 T allele also had significantly long overall survival compared to those who did not (P = 0.031). The researchers note that eNOS polymorphisms did not correlate with progression-free survival (P = 0.494).


  1. Gardini AC, Marisi G, Scarpi E, et al. eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. J Clin Oncol. 2015;33:(suppl 3; abstr 230). 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs